DekaBank Deutsche Girozentrale Increases Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

DekaBank Deutsche Girozentrale boosted its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 3.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,889 shares of the biotechnology company’s stock after purchasing an additional 1,272 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Arcturus Therapeutics were worth $1,401,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. New York State Teachers Retirement System purchased a new position in Arcturus Therapeutics in the 3rd quarter worth approximately $53,000. Great West Life Assurance Co. Can increased its stake in Arcturus Therapeutics by 29.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 2,679 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 616 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Arcturus Therapeutics by 352.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 2,406 shares during the period. Russell Investments Group Ltd. purchased a new position in Arcturus Therapeutics in the 1st quarter worth approximately $103,000. Finally, Point72 Middle East FZE purchased a new position in Arcturus Therapeutics in the 4th quarter worth approximately $79,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on ARCT shares. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. Citigroup lifted their price objective on Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, February 8th. Finally, William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Friday, March 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Arcturus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.33.

Arcturus Therapeutics Stock Down 6.5 %

Shares of ARCT stock opened at $30.43 on Monday. The stock has a market cap of $819.02 million, a price-to-earnings ratio of -29.26 and a beta of 2.60. The business’s fifty day moving average is $35.88 and its 200 day moving average is $29.71. Arcturus Therapeutics Holdings Inc. has a twelve month low of $17.52 and a twelve month high of $43.81.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($1.69) by $1.37. The company had revenue of $33.99 million for the quarter, compared to analysts’ expectations of $64.14 million. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. Equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -1.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Pad Chivukula sold 17,435 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $35.02, for a total value of $610,573.70. Following the sale, the chief operating officer now directly owns 473,448 shares of the company’s stock, valued at $16,580,148.96. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 13.80% of the stock is owned by insiders.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.